C. Max Schmidt
Appearances
- DateMay 9, 2023Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Presenter
Speakers
Indiana University School of MedicineIndiana University - DateMay 9, 2023Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Presenter
Speakers
Indiana UniversityIndiana University School of Medicine - DateMay 8, 2023BACKGROUND & AIMS: Minimal prospective data are available on intraoperative pancreatoscopy (IOP) for the diagnostic work-up of intraductal papillary mucinous neoplasia (IPMN)…
Speakers
Presenter
- DateMay 19, 2024BACKGROUND: Accurate clinical staging plays a key role in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC)…
Presenter
Speakers
Indiana UniversityIndiana University School of Medicine - DateMay 20, 2024Patients with chronic pancreatitis (CP) predominantly involving the pancreatic body/tail benefit from distal pancreatectomy (DP), with most experiencing long-term improvements in symptoms after recovery from surgery…
Presenter
Speakers
Indiana University School of MedicineIndiana University GOBLET CELL ADENOCARCINOMA AND RESPONSE TO TREATMENT - SINGLE CENTER EXPERIENCE OF A RARE MALIGNANCY
DateMay 21, 2024Goblet cell adenocarcinoma is a rare malignancy with an incidence of 1 per 2 million people worldwide…Presenter
Speakers
Indiana UniversityIndiana University School of Medicine- DateMay 21, 2024Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed after reaching an advanced stage. High-risk patients with genetic predisposition (ie…
